Hyperion Therapeutics Release: HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy  
11/12/2012 7:38:59 AM

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) announced today that the results of the Phase 2 HALT-HE Study were presented at the Presidential Plenary Session I of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver MeetingĀ®), in Boston, MA.